Institute of Metabonomics & Medical NMR, School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou 325035 , China.
Institute of Molecular Pharmacology, School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou 325035 , China.
J Proteome Res. 2019 Mar 1;18(3):1218-1227. doi: 10.1021/acs.jproteome.8b00847. Epub 2019 Jan 9.
Alzheimer's disease (AD) is regarded as a metabolic disorder, and more attention has been paid to brain metabolism. However, AD may also affect metabolism in the peripheral organs beyond the brain. In this study, therefore, we investigated metabolic changes in the liver, kidney, and heart of amyloid precursor protein/presenilin 1 (APP/PS1) mice at 1, 5, and 10 months of age by using H NMR-based metabolomics and chemometrics. Metabolomic results reveal that the liver was the earliest affected organ in APP/PS1 mice during amyloid pathology progression, followed by the kidney and heart. Moreover, a hypometabolic state was found in the liver of APP/PS1 mice at 5 months of age, and the disturbed metabolites were mainly involved in energy metabolism, amino acid metabolism, nucleic acid metabolism, as well as ketone and fatty acid metabolism. In conclusion, our results suggest that AD is a systemic metabolic dysfunction, and hepatic metabolic abnormality may reflect amyloid pathology progression.
阿尔茨海默病(AD)被认为是一种代谢紊乱,人们越来越关注大脑代谢。然而,AD 也可能影响大脑以外的外周器官的代谢。因此,在这项研究中,我们通过使用基于 H NMR 的代谢组学和化学计量学方法,研究了淀粉样前体蛋白/早老素 1(APP/PS1)小鼠在 1、5 和 10 个月时肝脏、肾脏和心脏的代谢变化。代谢组学结果表明,在淀粉样蛋白病理进展过程中,肝脏是 APP/PS1 小鼠最早受到影响的器官,其次是肾脏和心脏。此外,在 5 个月大的 APP/PS1 小鼠的肝脏中发现了低代谢状态,受干扰的代谢物主要涉及能量代谢、氨基酸代谢、核酸代谢以及酮体和脂肪酸代谢。总之,我们的结果表明 AD 是一种全身性代谢功能障碍,肝代谢异常可能反映淀粉样蛋白病理进展。